2010
DOI: 10.1038/ijo.2010.136
|View full text |Cite
|
Sign up to set email alerts
|

The effect of protease inhibitors derived from potato formulated in a minidrink on appetite, food intake and plasma cholecystokinin levels in humans

Abstract: In this study protease inhibition using PI2 in a minidrink at a dose of 30 mg, as commercially used, had no (functional) efficacy on a range of behavioral and physiological appetite and intake control measures.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
9
0
1

Year Published

2011
2011
2023
2023

Publication Types

Select...
6
3
1

Relationship

0
10

Authors

Journals

citations
Cited by 22 publications
(10 citation statements)
references
References 17 publications
(23 reference statements)
0
9
0
1
Order By: Relevance
“…The highest dosage of SLD used was 300 mg/kg. In previous clinical and in vivo studies (25,26), which employed ~15 mg/kg PPI II, satiety response and anti-obesity effects were observed.…”
Section: Introductionmentioning
confidence: 98%
“…The highest dosage of SLD used was 300 mg/kg. In previous clinical and in vivo studies (25,26), which employed ~15 mg/kg PPI II, satiety response and anti-obesity effects were observed.…”
Section: Introductionmentioning
confidence: 98%
“…Indeed, the consumption of 1.5 g of PI2 in a high-protein soup vehicle results in increased CCK levels and decreased energy intake in human subjects (65). However, when only 30 mg of PI2 is consumed in a minidrink, no such differences in appetite, food intake, and plasma CCK and glucose levels were observed (67). These studies suggest that large amounts of PI2 are needed to have physiological effects.…”
Section: Potatoesmentioning
confidence: 94%
“…Worse, to date most of the agents proposed or currently sold as "functional" food ingredients for appetite control appear to lack consistent support for efficacy, or are unsuitable or ineffective in desired food formats (Wiseman et al, 2008;Keogh et al, 2010;Appleton et al, 2011;Smit et al, 2011;Blom et al, 2011;Peters et al, 2009Peters et al, , 2011aVerhoef and Westerterp, 2011;Chan et al, 2012;Márquez et al, 2012). The market potential for such (proprietary) solutions makes them highly attractive, but the costs and time needed for developing ingredients that are truly novel (in terms of source, chemistry, or biological target) and which can be brought to market with regulatory approval and substantiated claims, are barriers to commercial investment and feasibility.…”
Section: Current Status Of "Functional" Approaches To Satietymentioning
confidence: 99%